Effectiveness of abatacept for patients with Sjögren’s syndrome associated with rheumatoid arthritis. An open label, multicenter, one-year, prospective study: ROSE (Rheumatoid Arthritis with Orencia Trial toward Sjögren’s syndrome Endocrinopathy) trial

Modern Rheumatology

Volumn 26, Issue 6, 2016, Pages 891-899

  Tsuboi, Hiroto ^a   Matsumoto, Isao ^a   Hagiwara, Shinya ^a   Hirota, Tomoya ^a   Takahashi, Hiroyuki ^a   Ebe, Hiroshi ^a   Yokosawa, Masahiro ^a   Yagishita, Mizuki ^a   Takahashi, Hidenori ^a   Kurata, Izumi ^a   Ohyama, Ayako ^a   Honda, Fumika ^a   Asashima, Hiromitsu ^a   Miki, Haruka ^a   Umeda, Naoto ^a   Kondo, Yuya ^a   Hirata, Shintaro ^b   Saito, Kazuyoshi ^b   Tanaka, Yoshiya ^b   Horai, Yoshiro ^c   Nakamura, Hideki ^c   Kawakami, Atsushi ^c   Sumida, Takayuki ^a   more..

^a UNIVERSITY OF TSUKUBA   (Japan)

^b UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^c NAGASAKI UNIVERSITY GRADUATE SCHOOL OF BIOMEDICAL SCIENCES   (Japan)

Author keywords

Abatacept; Rheumatoid arthritis; Sj gren s syndrome

Indexed keywords

ABATACEPT; C REACTIVE PROTEIN; IMMUNOGLOBULIN G; METHOTREXATE; PREDNISOLONE; RHEUMATOID FACTOR; ANTIRHEUMATIC AGENT;

ADULT; ANTHROPOMETRIC PARAMETERS; ARTICLE; BRONCHITIS; CLINICAL ARTICLE; CLINICAL TRIAL; COMPRESSION FRACTURE; CORNEA ULCER; DAS28; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DRY EYE; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HERPES ZOSTER; HUMAN; INFECTION; KERATOCONJUNCTIVITIS SICCA; MEDICATION COMPLIANCE; MIDDLE AGED; MULTICENTER STUDY; NUCLEAR MAGNETIC RESONANCE IMAGING; OBSERVATIONAL STUDY; PAROTID GLAND DISEASE; PHARYNGITIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; SALIVA VOLUME; SALIVARY GLAND BIOPSY; SCHIRMER TEST; SCORING SYSTEM; SIMPLIFIED DISEASE ACTIVITY INDEX; SINUSITIS; SJOEGREN SYNDROME; STOMATITIS; TREATMENT OUTCOME; URINARY TRACT INFECTION; VOMITING; XEROSTOMIA; AGED; ARTHRITIS, RHEUMATOID; COMPLICATION; MALE; SJOGREN'S SYNDROME;

ABATACEPT; ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; FEMALE; HUMANS; MALE; MIDDLE AGED; SJOGREN'S SYNDROME;

EID: 84979656454     PISSN: 14397595     EISSN: 14397609     Source Type: Journal    
DOI: 10.3109/14397595.2016.1158773     Document Type: Article

References (28)

1. C.Vitali, S.Bombardieri, R.Jonsson, H.M.Moutsopoulos, E.L.Alexander, S.E.Carsons, et al. Classification criteria for Sjögren’s syndrome:a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis. 2002;61:554–8.
2. H.Tsuboi, H.Asashima, C.Takai, S.Hagiwara, C.Hagiya, M.Yokosawa, et al. Primary and secondary surveys on epidemiology of Sjogren's syndrome in Japan. Mod Rheumatol. 2014;24:464–70.
3. D.Wang, Y.Li, Y.Liu, G.Shi, et al. The use of biologic therapies in the treatment of rheumatoid arthritis. Curr Pharm Biotechnol. 2014;15:542–8.
4. C.C.Mok Emerging biological therapies for systemic lupus erythematosus. Expert Opin Emerg Drugs. 2014;19:303–22.
5. S.Mozaffari, S.Nikfar, A.H.Abdolghaffari, M.Abdollahi, et al. New biologic therapeutics for ulcerative colitis and Crohn's disease. Expert Opin Biol Ther. 2014;14:583–600.
6. M.Lynch, B.Kirby, R.B.Warren Treating moderate to severe psoriasis—best use of biologics. Expert Rev Clin Immunol. 2014;10:269–79.
7. S.Vishwanath, M.Relan, L.Shen, J.L.Ambrus Jr, et al. Update on the use of biologics in vasculitides. Curr Pharm Biotechnol. 2014;15:558–62.
8. P.R.Sada, D.Isenberg, C.Ciurtin Biologic treatment in Sjögren's syndrome. Rheumatology (Oxford). 2015;54:219–30.
9. M.Ramos-Casals, P.Brito-Zerón, A.Sisó-Almirall, X.Bosch, A.G.Tzioufas, et al. Topical and systemic medications for the treatment of primary Sjögren's syndrome. Nat Rev Rheumatol. 2012;8:399–411.
10. S.Dass, S.J.Bowman, E.M.Vital, K.Ikeda, C.T.Pease, J.Hamburger, et al. Reduction of fatigue in Sjögren syndrome with rituximab:results of a randomised, double-blind, placebo-controlled pilot study. Ann Rheum Dis. 2008;67:1541–4.
11. J.M.Meijer, P.M.Meiners, A.Vissink, F.K.Spijkervet, W.Abdulahad, N.Kamminga, et al. Effectiveness of rituximab treatment in primary Sjögren's syndrome:a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2010;62:960–8.
12. V.Devauchelle-Pensec, X.Mariette, S.Jousse-Joulin, J.M.Berthelot, A.Perdriger, X.Puéchal, et al. Treatment of primary Sjögren syndrome with rituximab:a randomized trial. Ann Intern Med. 2014;160:233–42.
13. X.Mariette, P.Ravaud, S.Steinfeld, G.Baron, J.Goetz, E.Hachulla, et al. Inefficacy of infliximab in primary Sjögren's syndrome:results of the randomized, controlled Trial of Remicade in Primary Sjögren's Syndrome (TRIPSS). Arthritis Rheum. 2004;50:1270–6.
14. V.Sankar, M.T.Brennan, M.R.Kok, R.A.Leakan, J.A.Smith, J.Manny, et al. Etanercept in Sjögren's syndrome:a twelve-week randomized, double-blind, placebo-controlled pilot clinical trial. Arthritis Rheum. 2004;50:2240–5.
15. X.Mariette, R.Seror, L.Quartuccio, G.Baron, S.Salvin, M.Fabris, et al. Efficacy and safety of belimumab in primary Sjögren's syndrome:results of the BELISS open-label phase II study. Ann Rheum Dis. 2015;74:526–31.
16. N.Singh, P.L.Cohen The T cell in Sjogren's syndrome:force majeure, not spectateur. J Autoimmun. 2012;39:229–33.
17. T.Sumida, H.Tsuboi, M.Iizuka, T.Hirota, H.Asashima, I.Matsumoto, et al. The role of M3 muscarinic acetylcholine receptor reactive T cells in Sjögren's syndrome:a critical review. J Autoimmun. 2014;51:44–50.
18. S.Adler, M.Körner, F.Förger, D.Huscher, M.D.Caversaccio, P.M.Villiger, et al. Evaluation of histological, serological and clinical changes in response to abatacept treatment of primary Sjögren's syndrome:a pilot study. Arthritis Care Res (Hoboken). 2013;65:1862–8.
19. P.M.Meiners, A.Vissink, F.G.Kroese, F.K.Spijkervet, N.S.Smitt-Kamminga, W.H.Abdulahad,. Abatacept treatment reduces disease activity in early primary Sjogren's syndrome (open-label proof of concept ASAP study). Ann Rheum Dis. 2014;73:1393–6.
20. H.Tsuboi, I.Matsumoto, S.Hagiwara, et al. Efficacy and safety of abatacept for patients with Sjögren's syndrome associated with rheumatoid arthritis:rheumatoid arthritis with orencia trial toward Sjögren's syndrome Endocrinopathy (ROSE) trial - an open-label, one-year, prospective study - Interim analysis of 32 patients for 24 weeks. Mod Rheumatol. 2015;25:187–93.
21. F.C.Arnett, S.M.Edworthy, D.A.Bloch, D.J.McShane, J.F.Fries, N.S.Cooper, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31:315–24.
22. D.Aletaha, T.Neogi, A.J.Silman, J.Funovits, D.T.Felson, C.O.Bingham 3rd, et al. 2010 Rheumatoid arthritis classification criteria:an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010;62:2569–81.
23. T.Fujibayashi, S.Sugai, N.Miyasaka, Y.Hayashi, K.Tsubota, et al. Revised Japanese criteria for Sjögren’s syndrome (1999):availability and validity. Mod Rheumatol. 2004;14:425–34.
24. M.Yokosawa, H.Tsuboi, K.Nasu, C.Hagiya, S.Hagiwara, T.Hirota, et al. Usefulness of MR imaging of the parotid glands in patients with secondary Sjögren's syndrome associated with rheumatoid arthritis. Mod Rheumatol. 2015;25:415–20.
25. P.Guyot, P.Taylor, R.Christensen, L.Pericleous, C.Poncet, M.Lebmeier, et al. Abatacept with methotrexate versus other biologic agents in treatment of patients with active rheumatoid arthritis despite methotrexate:a network meta-analysis. Arthritis Res Ther. 2011;13:R204.
26. J.He, Y.Ding, M.Feng, J.Guon, X.Sun, J.Zhao, et al. Characteristics of Sjögren's syndrome in rheumatoid arthritis. Rheumatology (Oxford). 2013;52:1084–9.
27. R.Matsudaira, N.Tamura, F.Sekiya, M.Ogasawara, K.Yamanaka, Y.Takasaki, et al. Anti-Ro/SSA antibodies are an independent factor associated with an insufficient response to tumor necrosis factor inhibitors in patients with rheumatoid arthritis. J Rheumatol. 2011;38:2346–54.
28. M.Scarsi, L.Paolini, D.Ricotta, A.Pedrini, S.Piantoni, L.Caimi, et al. Abatacept reduces levels of switched memory B cells, autoantibodies, and immunoglobulins in patients with rheumatoid arthritis. J Rheumatol. 2014;41:666–72.